CanVirex AG

CanVirex is a spin-off from the Heidelberg University Hospital, founded in 2017 in Basel, Switzerland. The company develops novel immunotherapeutics for the treatment of cancer and has recently committed to using its unique technology to develop a vaccination for protection against COVID-19. CanVirex and Heidelberg University Hospital have signed a strategic collaboration agreement for the research and clinical development of measles-vectored therapeutics. The Heidelberg University Hospital offers a unique infrastructure for swift clinical translation of our most promising drug candidates. CanVirex has also forged strategic collaborations with key industry partners for GMP manufacturing and commercialization of our products. CanVirex collaborates with the DZIF (German Center for Infection Research) for the development of the COVID-19 vaccine.